APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 1:500~1:1000 |
Not tested in other applications.
Calculated MW
Product Note
Factor X (cleaved Ala41) antibody detects endogenous levels of fragment of activated FA10 resulting from cleavage adjacent to Ala41.
PROPERTIES
Form
Liquid
Buffer
PBS, 150mM NaCl, 50% Glycerol
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
The antiserum was produced against synthesized peptide derived from human Factor X (22-71).
Purification
Purified by antigen-affinity chromatography
From serum
Conjugation
Unconjugated
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET
Synonyms
F10 , FX , FXA , coagulation factor X , Factor X
Cellular Localization
Secreted
Background
This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015]
Database
Research Area
DATA IMAGES
|
GTX86931 WB Image
WB analysis of A549 cells treated with etoposide using GTX86931 Factor X (cleaved Ala41) antibody.
|
REFERENCE
There are currently no references for Factor X (cleaved Ala41) antibody (GTX86931). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Factor X (cleaved Ala41) antibody (GTX86931). Be the first to share your experience with this product.
